Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

Table 4

Therapeutic goals according to cardiovascular risk.

Variable	Baseline n = 92 (%)	8 weeks n = 92 (%)	16 weeks n = 92 (%)
Low and moderate CVR (n = 26)
LDL-c <115 or <100 mg/dL	5 (5.4)	21 (22.8)	20 (22.7)	0.001	0.001
High and very-high CVR (n = 66)
LDL-c <70 or <55 mg/dL	11 (12.0)	46 (50.0)	45 (48.9)	0.001	0.001
Non-HDL-c <130 or <100 mg/dL	18 (19.5)	51 (55.4)	52 (56.5)	0.001	0.001

CVR: cardiovascular risk. For the baseline visit, data were only available for 79 patients out of the 92 for whom CVR was calculated, 89 for 8 weeks and 88 for 16 weeks. : comparison baseline vs. 8 weeks; : comparison baseline vs 16 weeks; the McNemar’s test was used for this evaluation. The PAHO/WHO—PAHO calculator was used to calculate CVR.